cagrilintide semaglutide cagrisema phase 3 results 2024 2025 Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes CagriSema Did Not Meet Primary

A company that applies once is taking a single shot

The results have been consistently promising across multiple tissue types and organ systems, though large-scale human clinical trials remain limited

These often ease as the body adapts

And so, started with 111

Luxxe White Coffee: A health and beauty coffee sweetened with stevia, featuring premium Japanese collagen, L-glutathione, and superfoods like grape seed and moringa

In addition to changes in body weight, changes in BMI and cardiometabolic biomarkers (where available) were reported over the course of a 6month followup period among US adult patients who escalated to the maintenance dose of semaglutide at 2.4 mg per FDA label during the study time